Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, has agreed to use its lead cancer product, DPX-Survivac,
in a study based in Rome designed to extend life for glioblastoma patients. The
multicenter trial will be led by Professor Marianna Nuti, Ph.D., Department of
Experimental Medicine at the University of Rome, and conducted in collaboration
with neurosurgeons and oncologists coordinated by Professor Maurizio Salvati,
M.D. Four major trial centers across Italy will be involved, with the cost of
the trial being assumed by the university. The randomized, placebo-controlled
study will enroll more than 50 patients with newly diagnosed brain tumors that
have been maximally resected. The study is expected to start in Q4 of 2013. 


The Phase II study will evaluate DPX-Survivac therapy in combination with
temozolomide, the standard of care therapy for newly diagnosed gliobastoma
patients following surgery and radiation. With current standard of care, median
overall survival for newly diagnosed glioblastoma patients is less than 24
months with median time to disease recurrence less than seven months.
Temozolomide is used in both the front-line and maintenance setting in treating
patients with glioblastoma. It has been reported to have immune-modulating
effects making it a suitable drug to combine with cancer vaccines. DPX-Survivac
will be applied only during the temozolomide maintenance phase. 


Patients will be randomized into three groups to receive either DPX-Survivac; a
dendritic cell (DC) based survivin vaccine; or, the standard of care with a
placebo vaccine. The primary goal of the study is to evaluate the effectiveness
of DPX-Survivac. Secondary endpoints will include progression-free survival and
overall survival following the proposed combination therapy. Initial data from
this trial is expected in the second half of 2014. 


"We are enthusiastic to apply DPX-Survivac in glioblastoma patients," stated Dr.
Nuti. "This type of tumor has been demonstrated to express survivin at a high
level and DPX-Survivac has demonstrated promising immunogenicity in a clinical
trial in ovarian cancer patients. We hope to achieve similar immunogenicity in
glioblastoma patients."


Marc Mansour, chief science officer of Immunovaccine, said, "A survivin vaccine
has broad utility across different cancer types, and glioblastoma is a good
setting for testing the immunologic effects of DPX-Survivac. This trial allows
us to test DPX-Survivac with an interesting immune modulator and in a minimal
residual disease setting. This adheres to our principles for applying a
therapeutic vaccine in patients with metastatic disease." 


Earlier this year, Immunovaccine announced positive results from the Company's
Phase I clinical trial of DPX-Survivac. Data showed all patients that had
received DPX-Survivac in combination with cyclophosphamide produced targeted
immune responses and that there were multiple strong responders among this group
who presented circulating target and sustained specific T cells (CD8 T cells) in
their blood. 


The presence of circulating CD8 T cells is critical in treating cancer because
these particular T cells are implicated in identifying cancer cells,
infiltrating tumors and killing cancer targets. Data also demonstrated that the
vaccine had no systemic side effects or dose limiting toxicities. 


About Glioblastoma

Glioblastoma, the most common form of brain cancer, is a fast-growing tumor type
that develops from astrocytes, a type of glial cell present in the brain. The
National Cancer Institute estimates that more than 23,000 Americans will be
diagnosed with brain and other nervous system tumors in 2013. Glioblastoma
accounts for approximately 15 percent of all brain tumors. The current standard
of care for glioblastoma patients is maximum surgical resection combined with
radiation and concomitant and adjuvant temozolomide therapy. Median overall
survival for newly diagnosed glioblastoma patients is less than 24 months.


About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in multiple cancer types in addition to ovarian cancer, including
breast, colon and lung cancers. Survivin plays an essential role in antagonizing
apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to
various anti-cancer therapies. Survivin is also a prognostic factor for many
cancers and it is found in a higher percentage of tumors than other TAA's.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to search
actively and specifically for tumor cells and destroy them. Survivin-specific
T-cells have been shown to target and kill survivin-expressing cancer cells
while sparing normal cells.


About DepoVax(TM)

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax(TM) platform possesses impressive flexibility,
allowing it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a broad infectious
diseases pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at
www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Dr. Marc Mansour
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7400
tbrons@vidasp.com